Abstract
Cognitive sequelae of opioid treatments for chronic pain are an important clinical concern. To assess cognitive effects of oxymorphone extended release (ER; 15 and 30 mg) and oxycodone controlled release (CR; 30 and 60 mg) in healthy nondependent recreational opioid users, an exploratory, randomized, double-blind, placebo-controlled 5-way crossover study was conducted. Subjects received single oral intact doses of opioids and placebo with a ≥7-day washout period between treatments. Sedation and cognitive effects were assessed using the Addiction Research Center Inventory Pentobarbital-Chlorpromazine-Alcohol Group (PCAG) scale, Alertness/Drowsiness Visual Analog Scale (A/D-VAS), and Divided Attention (DA) test.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.